Epic Systems Leverages National Health Records to Track Unreported Medical Conditions

Key facts

According to reporting published by The Capital Times on September 21, 2026, healthcare technology provider Epic Systems is systematically transforming raw clinical data generated during routine medical appointments into aggregate public health intelligence. The Madison-area outlet reported that Epic's analytical systems allow researchers to study population-wide medical trends, specifically focusing on diagnoses, symptoms, and treatment responses that operate outside government-mandated health registries.

During the initial testing phase of these data tools, Epic engineers and clinical researchers evaluated how anonymized data extracted from electronic medical charts could identify disease patterns before traditional public health channels registered them. As detailed in The Capital Times report, internal testing demonstrated that aggregating routine clinical documentation—including physician diagnostic codes, laboratory test results, prescription orders, and clinical notes—could provide immediate visibility into non-reportable conditions that historically lacked centralized tracking.

Under long-standing public health frameworks in the United States, medical providers are legally required to report a narrow set of communicable diseases, such as measles, viral hepatitis, tuberculosis, and novel respiratory illnesses, to local, state, and federal health departments. However, thousands of other health conditions—ranging from autoimmune flare-ups, metabolic disorders, and localized allergic reactions to adverse drug interactions and mental health crises—do not trigger mandatory state notifications. Epic's research platform addresses this structural information gap by pooling de-identified data from participating health systems that deploy its software.

By standardizing and aggregating clinical entries across participating hospitals, clinics, and specialty centers, the software company enables epidemiologists and medical researchers to query vast datasets. This capability allows analysts to track shifts in disease incidence, measure treatment efficacy across diverse demographic groups, and identify emerging public health issues without relying on manual case reporting or dedicated clinical trial enrollment.

Why it matters

The expansion of private health data aggregation represents a fundamental shift in how public health intelligence is gathered, analyzed, and applied in clinical practice. Historically, epidemiological surveillance suffered from substantial time lags. Traditional public health reporting depends on individual clinicians or laboratories identifying a mandatory reportable condition, filling out administrative forms, and submitting them to county or state health departments, which then clean and aggregate the data before transmitting it to the Centers for Disease Control and Prevention (CDC). This multi-step process can introduce delays ranging from several weeks to many months, leaving health authorities blind to rapidly evolving health emergencies or subtle epidemiological shifts.

By contrast, real-world data (RWD) platforms that extract information directly from electronic health records cut reporting latency from months to hours. When millions of clinical encounters are continuously ingested into an aggregated system, subtle statistical anomalies—such as an unseasonal spike in pediatric respiratory symptoms or a cluster of unexpected liver enzyme elevations following the approval of a new prescription drug—can be detected almost instantaneously.

Furthermore, monitoring non-reportable conditions fills a major void in clinical research. Chronic illnesses, environmental exposure responses, and lifestyle-related conditions account for the vast majority of healthcare expenditure and mortality in developed nations, yet they are rarely tracked through centralized public health infrastructure. Systematic EHR aggregation allows medical researchers to observe the real-world performance of medications, track long-term chronic disease trajectories, and evaluate health disparities across different socioeconomic and geographic populations.

However, the concentration of such enormous volumes of sensitive health data within a private enterprise raises important policy and ethical considerations. Questions surrounding data governance, commercialization rights, patient privacy protections, and potential algorithmic bias are central to public discussions as commercial EHR vendors become central nodes in national health surveillance.

To understand the significance of Epic Systems' health data initiatives, it is necessary to examine the evolution of electronic health records in the United States over the past two decades. Founded in 1979 by Judy Faulkner in a basement office in Madison, Wisconsin, Epic Systems grew from a small database management company into the dominant electronic health record vendor in North America.

The company's trajectory was fundamentally reshaped by federal legislation. In 2009, the United States Congress passed the Health Information Technology for Economic and Clinical Health (HITECH) Act as part of the American Recovery and Reinvestment Act. The HITECH Act allocated tens of billions of dollars in federal financial incentives to hospitals and medical practices that adopted certified EHR systems, while penalizing institutions that maintained paper records. This regulatory mandate triggered a rapid digitization of American healthcare.

Over the subsequent decade, Epic captured a commanding share of the enterprise hospital market, particularly among large academic medical centers, integrated health networks, and multi-specialty medical groups. Today, Epic's software holds the medical records of an estimated 250 million Americans, spanning hundreds of health systems and thousands of hospitals and clinics.

Recognizing the research potential of this massive data footprint, Epic developed aggregated platforms such as Epic Cosmos, a secondary research database composed of de-identified patient records voluntarily contributed by participating healthcare organizations. Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule, patient health information can be used for secondary research purposes without individual patient authorization if it has been thoroughly de-identified according to federal Safe Harbor guidelines or expert determination methods.

While government public health surveillance has historically been constrained by federalist division of powers—where public health authority rests primarily with individual states rather than a single national agency—private EHR platforms operate seamlessly across state lines. This structural advantage allows private technology vendors to aggregate cross-jurisdictional clinical data at a scale that federal agencies have historically struggled to achieve.

Reaction

The utilization of routine EHR data for public health tracking and clinical research has drawn reactions from epidemiologists, healthcare administrators, privacy advocates, and regulatory authorities.

Public health researchers and clinical epidemiologists have broadly welcomed the integration of real-world clinical data into public health surveillance, citing the ability to conduct observational studies on millions of patient lives without the multi-million-dollar overhead and lengthy timelines of traditional randomized controlled trials. Public health officials have noted that real-time EHR monitoring proved vital during the COVID-19 pandemic, when rapid insights into hospitalization rates, vaccine effectiveness, and therapeutic outcomes were urgently needed.

Conversely, patient advocacy organizations and bioethicists have expressed caution regarding the governance of aggregated medical data. Privacy scholars frequently highlight that while HIPAA permits the secondary use of de-identified records, advanced data analytics and secondary linking mechanisms present theoretical risks of re-identification. Furthermore, bioethicists point out that most patients remain unaware that their de-identified clinical notes, lab results, and diagnostic histories are pooled into commercial research databases, as standard HIPAA consent paperwork signed at doctor visits covers secondary research uses under broad terms.

Health system leaders and chief medical information officers participating in data-sharing initiatives must balance the clinical benefits of shared research against operational security, proprietary data rights, and patient trust.

What we don't know yet

Despite the details provided by The Capital Times, several critical operational and technical aspects of Epic's data platform remain unclarified in the available reporting:

What to watch

Looking ahead, several key developments and milestones will determine how real-world EHR data aggregation shapes public health and medical research:

This report is based on original reporting published by The Capital Times on September 21, 2026.